ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Sees Large Increase in Short Interest

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 20,657 shares, a growth of 407.4% from the March 31st total of 4,071 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average daily volume of 27,055 shares, the short-interest ratio is currently 0.8 days.

Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF

A number of hedge funds have recently added to or reduced their stakes in SBIO. Delta Investment Management LLC acquired a new position in ALPS Medical Breakthroughs ETF during the 4th quarter valued at about $6,112,000. LPL Financial LLC boosted its stake in ALPS Medical Breakthroughs ETF by 438.7% during the 4th quarter. LPL Financial LLC now owns 42,755 shares of the company’s stock valued at $2,190,000 after purchasing an additional 34,819 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in ALPS Medical Breakthroughs ETF during the 1st quarter valued at about $782,000. Stifel Financial Corp acquired a new position in ALPS Medical Breakthroughs ETF during the 4th quarter valued at about $1,018,000. Finally, Virtu Financial LLC acquired a new position in ALPS Medical Breakthroughs ETF during the 3rd quarter valued at about $650,000.

ALPS Medical Breakthroughs ETF Price Performance

SBIO stock traded down $0.18 during mid-day trading on Friday, reaching $54.41. 23,622 shares of the company traded hands, compared to its average volume of 38,777. ALPS Medical Breakthroughs ETF has a fifty-two week low of $26.86 and a fifty-two week high of $57.77. The firm’s 50 day moving average price is $52.05 and its 200 day moving average price is $49.72.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.